Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2023-11-26 |
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Library ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "179632"] ; #
fhir:meta [
fhir:versionId [ fhir:v "4" ] ;
fhir:lastUpdated [ fhir:v "2023-12-15T13:02:51.862Z"^^xsd:dateTime ] ;
( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "extensions" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<div>\n <table class=\"grid dict\">\n \n \n <tr>\n <th scope=\"row\"><b>Title: </b></th>\n <td style=\"padding-left: 4px;\">SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</td>\n </tr>\n \n\n \n \n <tr>\n <th scope=\"row\"><b>Id: </b></th>\n <td style=\"padding-left: 4px;\">179632</td>\n </tr>\n \n\n \n \n <tr>\n <th scope=\"row\"><b>Version: </b></th>\n <td style=\"padding-left: 4px;\">2.0.0-ballot</td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Url: </b></th>\n <td style=\"padding-left: 4px;\"><a href=\"Library-179632.html\">SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</a></td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\">\n <b>\n \n \n Accession ID (Computable Publishing LLC) Identifier:\n \n \n </b>\n </th>\n <td style=\"padding-left: 4px;\">\n \n <p style=\"margin-bottom: 5px;\">\n <span>179632</span>\n </p>\n \n </td>\n </tr>\n \n <tr>\n <th scope=\"row\">\n <b>\n \n \n \n </b>\n </th>\n <td style=\"padding-left: 4px;\">\n \n <p style=\"margin-bottom: 5px;\">\n <span>urn:oid:2.16.840.1.113883.4.642.40.44.28.2</span>\n </p>\n \n </td>\n </tr>\n \n\n \n\n \n\n \n\n \n <tr>\n <th scope=\"row\"><b>Type: </b></th>\n <td style=\"padding-left: 4px;\">\n \n \n \n <p style=\"margin-bottom: 5px;\">\n <b>system: </b> <span><a href=\"http://terminology.hl7.org/6.1.0/CodeSystem-library-type.html\">http://terminology.hl7.org/CodeSystem/library-type</a></span>\n </p>\n \n \n <p style=\"margin-bottom: 5px;\">\n <b>code: </b> <span>asset-collection</span>\n </p>\n \n \n <p style=\"margin-bottom: 5px;\">\n <b>display: </b> <span>Asset Collection</span>\n </p>\n \n \n \n \n </td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Subject: </b></th>\n \n \n <td style=\"padding-left: 4px;\">\n \n <p style=\"margin-bottom: 5px;\">\n <b>reference: </b> <span>Group/179619</span>\n </p>\n \n \n <p style=\"margin-bottom: 5px;\">\n <b>type: </b> <span><a href=\"http://hl7.org/fhir/R5/group.html\">http://hl7.org/fhir/StructureDefinition/Group</a></span>\n </p>\n \n \n <p style=\"margin-bottom: 5px;\">\n <b>code: </b> <span>SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer</span>\n </p>\n \n </td>\n \n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Date: </b></th>\n <td style=\"padding-left: 4px;\">2023-11-26 18:15:27+0000</td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Publisher: </b></th>\n <td style=\"padding-left: 4px;\">HL7 International / Clinical Decision Support</td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Description: </b></th>\n <td style=\"padding-left: 4px;\"><div><p>11 excluded studies</p>\n</div></td>\n </tr>\n \n\n \n\n \n\n \n <tr>\n <th scope=\"row\"><b>Use Context: </b></th>\n <td style=\"padding-left: 4px;\">\n <table class=\"grid-dict\">\n <tr>\n <th><b>code</b></th>\n <th><b>value</b></th>\n </tr>\n \n <tr>\n <td>evidence-communication</td>\n <td/>\n </tr>\n \n </table>\n </td>\n </tr>\n \n\n \n <tr>\n <th scope=\"row\"><b>Jurisdiction: </b></th>\n <td style=\"padding-left: 4px;\">001</td>\n </tr>\n \n\n \n\n \n\n \n\n \n <tr>\n <th scope=\"row\"><b>Copyright: </b></th>\n <td style=\"padding-left: 4px;\"><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>\n</div></td>\n </tr>\n \n\n \n\n \n\n \n <tr>\n <th scope=\"row\"><b>Related Artifacts: </b></th>\n <td style=\"padding-left: 4px;\">\n \n \n \n \n \n <p><b>Derived From</b></p>\n <ul>\n \n <li/>\n \n </ul>\n \n \n \n </td>\n </tr>\n \n\n \n\n \n\n \n </table>\n</div>\n</div>"
] ; #
fhir:url [ fhir:v "https://fevir.net/resources/Library/179632"^^xsd:anyURI] ; #
fhir:identifier ( [
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ] ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ] ] ;
fhir:system [ fhir:v "https://fevir.net"^^xsd:anyURI ] ;
fhir:value [ fhir:v "179632" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ] ]
] [
fhir:system [ fhir:v "urn:ietf:rfc:3986"^^xsd:anyURI ] ;
fhir:value [ fhir:v "urn:oid:2.16.840.1.113883.4.642.40.44.28.2" ]
] ) ; #
fhir:version [ fhir:v "2.0.0-ballot"] ; #
fhir:title [ fhir:v "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"] ; #
fhir:status [ fhir:v "active"] ; #
fhir:experimental [ fhir:v "false"^^xsd:boolean] ; #
fhir:type [
( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/library-type"^^xsd:anyURI ] ;
fhir:code [ fhir:v "asset-collection" ] ;
fhir:display [ fhir:v "Asset Collection" ] ] )
] ; #
fhir:subject [
a fhir:Reference ;
fhir:reference [ fhir:v "Group/179619" ] ;
fhir:type [ fhir:v "Group"^^xsd:anyURI ] ;
fhir:display [ fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer" ]
] ; #
fhir:date [ fhir:v "2023-11-26T18:15:27.442Z"^^xsd:dateTime] ; #
fhir:publisher [ fhir:v "HL7 International / Clinical Decision Support"] ; #
fhir:contact ( [
fhir:name [ fhir:v "HL7 International / Clinical Decision Support" ] ;
( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://www.hl7.org/Special/committees/dss" ] ] )
] ) ; #
fhir:description [ fhir:v "11 excluded studies"] ; #
fhir:useContext ( [
fhir:code [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "evidence-communication" ] ;
fhir:display [ fhir:v "Evidence Communication" ] ] ;
fhir:value [
a fhir:CodeableConcept ;
( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SystematicReviewExcludedStudies" ] ;
fhir:display [ fhir:v "SystematicReviewExcludedStudies" ] ] ) ]
] ) ; #
fhir:jurisdiction ( [
( fhir:coding [
fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ] ;
fhir:code [ fhir:v "001" ] ;
fhir:display [ fhir:v "World" ] ] )
] ) ; #
fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; #
fhir:author ( [
fhir:name [ fhir:v "Brian S. Alper" ]
] ) ; #
fhir:relatedArtifact ( [
fhir:type [ fhir:v "derived-from" ] ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179613" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus estramustine)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179628" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus chemotherapy without docetaxel)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179631" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179627" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179626" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179625" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179629" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Neoadjuvant treatment" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179624" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179622" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "High-risk localized prostate cancer" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179621" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Locally advanced or metastatic (without metastatic subgroup analysis)" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179630" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer." ] ]
] [
fhir:type [ fhir:v "contains" ] ;
( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ] ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179623" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer." ] ]
] ) . #
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change